SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference.
The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer).
Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – (https://illumina-agbt-investor-session-feb-2025.open-exchange.net/) To ensure timely connection, please join at least ten minutes before the scheduled start of the session.
A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Bonny Fowler
+1.740.641.5579
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$127.25 |
| Daily Change: | -1.71 -1.33 |
| Daily Volume: | 1,309,148 |
| Market Cap: | US$19.440B |
November 12, 2025 November 11, 2025 November 05, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
